Biotech Bonanza (Goldseeker) That is why Recaf will be #1 in cancer diagnostics.

It has very VERY few false positives according to Abbott and Goshen and Blokhin.

Specificity represents how well the test avoids false positives (no false positives = 100% specificity). The regression coefficient (r) between the RECAF-ELISA and the RECAF-chemiluminescence test was 0.92 (maximum = 1) and the diagnostic correspondence between both tests was 97.8%. The work was done in collaboration with the Blokhin Cancer Research Centre, Moscow, Russia, and BioCurex expects to present the results at an International cancer congress later this year.